Literature DB >> 19969291

Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.

MaryFran Sowers1, Daniel McConnell2, Katherine Gast3, Huiyong Zheng2, Bin Nan4, Jenifer D McCarthy3, John F Randolph3.   

Abstract

OBJECTIVE: To describe anti-Müllerian hormone (AMH) variation across normal menstrual cycles.
DESIGN: Cohort study.
SETTING: Academic environment. PATIENT(S): Twenty regularly menstruating women. INTERVENTION(S): Serum AMH and inhibin B assayed daily during one normal menstrual cycle. MAIN OUTCOME MEASURE(S): Intracycle variability of AMH and inhibin B. RESULT(S): Data were classified into quartiles of AMH area-under-the-curve (AUCs). Mean AMH AUC was 15.7 ng/mL for quartile 1 versus 43.5, 80.9 and 144.9 ng/mL for quartiles 2, 3, and 4. Mean AMH levels (ng/mL) were 0.67, 1.71, 3.02, and 5.33, respectively. There was no variation in quartile 1 AMH rate of change from stochastic modeling, but in quartiles 2 to 4, there were increased rates of change in days 2 to 7. Women in quartile 1 had the lowest mean inhibin B (24.2 pg/mL vs. 44.3, 43.2, and 42.2 pg/mL), and had shorter menstrual cycles (24.6 days) than women in quartiles 3 and 4 (28.2 and 28.4 days). CONCLUSION(S): There were two menstrual cycle patterns of AMH. The "aging ovary" pattern included low AMH levels with little variation, lower inhibin B, and shorter cycle lengths. The "younger ovary" pattern included higher AMH levels with significant variation days 2 to 7, suggesting that for women with AMH>1 ng/mL, the interpretation of AMH levels is contingent upon the day of the menstrual cycle on which the specimen is obtained. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969291      PMCID: PMC2891288          DOI: 10.1016/j.fertnstert.2009.07.1674

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  18 in total

1.  Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation.

Authors:  Antonio La Marca; Stefania Malmusi; Simone Giulini; Leo Fischer Tamaro; Raoul Orvieto; Paola Levratti; Annibale Volpe
Journal:  Hum Reprod       Date:  2004-09-30       Impact factor: 6.918

2.  High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status.

Authors:  Renato Fanchin; Joëlle Taieb; Daniel H Mendèz Lozano; Béatrice Ducot; René Frydman; Jean Bouyer
Journal:  Hum Reprod       Date:  2005-01-07       Impact factor: 6.918

3.  Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system.

Authors:  Georgina E Hale; Xue Zhao; Claude L Hughes; Henry G Burger; David M Robertson; Ian S Fraser
Journal:  J Clin Endocrinol Metab       Date:  2007-06-05       Impact factor: 5.958

4.  Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women.

Authors:  S Tsepelidis; F Devreker; I Demeestere; A Flahaut; Ch Gervy; Y Englert
Journal:  Hum Reprod       Date:  2007-05-07       Impact factor: 6.918

Review 5.  Clinical implications of ovarian reserve testing.

Authors:  Anne Z Steiner
Journal:  Obstet Gynecol Surv       Date:  2009-02       Impact factor: 2.347

6.  A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles.

Authors:  David M Robertson; Georgina E Hale; Ian S Fraser; Claude L Hughes; Henry G Burger
Journal:  Menopause       Date:  2008 Nov-Dec       Impact factor: 2.953

7.  Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles.

Authors:  N A Klein; P J Illingworth; N P Groome; A S McNeilly; D E Battaglia; M R Soules
Journal:  J Clin Endocrinol Metab       Date:  1996-07       Impact factor: 5.958

8.  Serum müllerian-inhibiting substance levels during normal menstrual cycles.

Authors:  C L Cook; Y Siow; S Taylor; M E Fallat
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

Review 9.  Initial and cyclic recruitment of ovarian follicles.

Authors:  E A McGee; A J Hsueh
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

Review 10.  Regulation and function of inhibins in the normal menstrual cycle.

Authors:  Corrine K Welt
Journal:  Semin Reprod Med       Date:  2004-08       Impact factor: 1.303

View more
  28 in total

1.  Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.

Authors:  W Marder; W J McCune; L Wang; J J Wing; S Fisseha; D S McConnell; G M Christman; E C Somers
Journal:  Gynecol Endocrinol       Date:  2012-02-02       Impact factor: 2.260

2.  AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level.

Authors:  Lisa M Pastore; Timothy L McMurry; Christopher D Williams; Valerie L Baker; Steven L Young
Journal:  J Assist Reprod Genet       Date:  2014-06-18       Impact factor: 3.412

3.  Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle.

Authors:  John F Randolph; Siobán D Harlow; Margaret E Helmuth; Huiyong Zheng; Daniel S McConnell
Journal:  Hum Reprod       Date:  2013-12-18       Impact factor: 6.918

4.  Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH.

Authors:  Crystal Chan; Kimberly Liu
Journal:  J Assist Reprod Genet       Date:  2014-08-12       Impact factor: 3.412

5.  Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women.

Authors:  K A Kissell; M R Danaher; E F Schisterman; J Wactawski-Wende; K A Ahrens; K Schliep; N J Perkins; L Sjaarda; J Weck; S L Mumford
Journal:  Hum Reprod       Date:  2014-06-12       Impact factor: 6.918

6.  Multi-center clinical evaluation of the Access AMH assay to determine AMH levels in reproductive age women during normal menstrual cycles.

Authors:  Clarisa R Gracia; Sanghyuk S Shin; Maureen Prewitt; Janna S Chamberlin; Lori R Lofaro; Kristin L Jones; Marta Clendenin; Katherine E Manzanera; Dennis L Broyles
Journal:  J Assist Reprod Genet       Date:  2018-03-14       Impact factor: 3.412

Review 7.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

8.  Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception.

Authors:  Lauren N C Johnson; Mary D Sammel; Katherine E Dillon; Lara Lechtenberg; Allison Schanne; Clarisa R Gracia
Journal:  Fertil Steril       Date:  2014-06-14       Impact factor: 7.329

9.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

10.  Evaluation of ovarian reserve after laparoscopic surgery in patients with polycystic ovary syndrome.

Authors:  Laya Farzadi; Mohammad Nouri; Morteza Ghojazadeh; Mona Mohiti; Esmat Aghadavod
Journal:  Bioimpacts       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.